Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Press Releases
Events & Presentations
August 4, 2022
Phase II Drug Development for Alzheimer’s Disease: Athira Pharma
Scientific Presentation
August 3, 2022
ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial
Scientific Presentation
August 2, 2022
Fosgonimeton, a Novel, Small-Molecule Positive Modulator of the HGF/MET System, is Neuroprotective in Primary Neuron Culture
Scientific Presentation